Call for Abstract

13th World Biomarkers Congress, will be organized around the theme “Advances in Biomarker Research”

World Biomarkers 2018 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in World Biomarkers 2018

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

A biomarker can be anything that can be accurately measured as an indicator of normal biological functioning, pathogenic paths or a drug response to a therapeutic drug intervention.  Biomarkers are usually in molecular form. Biomarkers take part in various purposes, including disease diagnosis and prognosis, prediction and calculation of treatment response, and safety evaluation. The   Biomarkers are exclusively being developed and validated to be used in drug development, and used to support approval of drug products.
Biomarkers are mainly classified into Protein biomarkers, Nucleic acid based biomarkers, Lipid biomarkers and Small molecule biomarkers. Almost every pharmaceutical company has been developing biomarker programs. There has been a rapid increase in the number of Biomarkers Congress used in drug delivery over the last decade.


  • Track 1-1Protein Biomarkers
  • Track 1-2Nucleic acid biomarkers
  • Track 1-3Lipid biomarkers
  • Track 1-4Small molecule biomarkers

A cancer biomarker is an element or procedure that indicates the presence of cancer in the body. A biomarker may be any molecule released by presence a tumor or a specific indication of the body to the presence of cancer. Cancer biomarkers are usually biological molecules found in blood, other body fluids, or tissues that are a sign of a normal or abnormal process, or of a condition or disease.Cancer biomarkers can be classified into Nucleic acid based biomarkers, Pathological biomarkers, In silico biomarkers, Imaging biomarkers and Glycoprotein biomarkers based on their structure and functioning. All these topics are discussed in these cancer biomarker conferences.


  • Track 2-1Genetic biomarkers
  • Track 2-2Pathological biomarkers
  • Track 2-3In silico bioamarkers
  • Track 2-4Imaging biomarkers
  • Track 2-5Glycoprotien biomarkers

Biomarkers which are used for clinical purposes are called clinical biomarkersClinical biomarkers along with provide a vibrant and influential methodology to understanding the range of many diseases with uses in judgemental and  analytic epidemiologyarbitrary clinical trials, screening for drugs or disease diagnosis and prognosis. Defined as changes in the constituents of cells or body fluids, these clinical biomarkers offer the means for standardized classification of a disease and risk factors, and the can extend the base information about the underlying pathogenesis of disease.The main researches in clinical biomarkers are done in the fields of drug discoveryoncology, pharmacogenomics  and disease diagnostics. 


  • Track 3-1Clinical biomarkers in drug discovery
  • Track 3-2Clinical biomarkers in oncology
  • Track 3-3Clinical biomarkers and pharmacogenomics
  • Track 3-4Clinical biomarkers in diagnostics

Biomarkers play a significant role in cancer prognosis, diagnosis and treatment of cancers these days. There are many types of cancers which are hard to even diagnose. The latest designed biomarkers and their applications provide a great advantage in these cases. Cancer Epidemiology, treatment and latest research is greatly relayed on the biomarkers.
The major types of cancers in which biomarkers are widely being used are breast cancer, lung cancer, prostate cancer and blood cancer. Cancer biomarkers conferences provide a good platform for elaborated discussion on various new researches.


  • Track 4-1Biomarkers for breast cancer
  • Track 4-2Biomarkers for lung cancer
  • Track 4-3Biomarkers for prostate cancer
  • Track 4-4Biomarkers for blood cancer
  • Track 4-5Biomarkers for adrenal cancer
  • Track 4-6Biomarkers for colorectal cancer
  • Track 4-7Biomarkers for gastric cancer

Biomarkers plan an important role in various neurological and cardiovascular diseases. The diseases which are incurable from ages are being offered a possible treatment and easy diagnosis with the help of advancements in biomarkers through different diagnostics and imaging technologies. Cardiac biomarkers and neuro biomarkers has brought a great revolution in disease diagnosis and prognosis. Biomarkers are used in many other non-cancerous diseases. Some of the important ones are Alzheimer’s disease, Neurodegenerative diseases, cardiovascular diseases, and Huntington's disease. 


  • Track 5-1Biomarkers for Alzheimer’s
  • Track 5-2Biomarkers for Cardiovascular diseases
  • Track 5-3Biomarkers for Neurodegenerative diseases
  • Track 5-4Biomarkers for diabetes
  • Track 5-5Biomarkers for Huntington s disease
  • Track 5-6Biomarkers for Behcet s disease

Biomarker discovery requires highly assured identification of a biomarker with real-time quantitative information to indicate which proteins are altering to a statistically pertinent degree in response to disease. The discovery of  biomarkers has developed new strategies starting from the initial steps. In the first stage of biomarker discovery proceedings, investigation depends upon mass spectrometry techniques to make unbiased, semiquantitative analysis of changes between healthy and diseased states. The slope of probable biomarkers generated in the discovery stage is to be further substantiated due to the high false positive rate. It is done through supplemental more targeted and quantitative mass spectrometry techniques, such as immuno affinity peptide enrichment.

Under this track, the latest trends in discovery and development of biomarkers and biomarker identification are discussed. There are many new strategies being fashioned in development of biomarkers. In this section advancements of biomarkers in various sectors like clinical biomarkers, paediatric diseases biomarkers, and clinical analysis of NGS samples are covered.


  • Track 6-1New strategies for discovery
  • Track 6-2Protein biomarker discovery
  • Track 6-3Clinical biomarker advances
  • Track 6-4Biomarkers for paediatric diseases
  • Track 6-5Biomarkers for paediatric diseases
  • Track 6-6Clinical analysis of NGS samples
  • Track 6-7Mass spectrometry based biomarker discovery

Biomarker testing is a group of tests that looks for the molecular signs of health so that doctors can plan the best care. Biomarker testing can also be called as genetic testing or biomarkers testing.  Biomarkers, a foundation of precision oncology, are very important in management of breast cancer, gastro-esophageal cancer and non-small cell lung cancer. Testing practices are intensely deliberated, influencing diagnostic quality and affecting pathologists, oncologists and patients.

The advances in biomarker testing are mainly in the fields of genetic testing, cancers and other diseases in their diagnosis, treatment and imaging. In silico biomarkers, microRNA biomarkers and several other clinical biomarkers evolved in the recent researches have opened up the path for biomarker testing broader.


  • Track 7-1Genetic testing and Molecular Biomarkers
  • Track 7-2Biomarker testing for cancers
  • Track 7-3Biomarker testing for other diseases
  • Track 7-4Biomarker testing in diagnosis

Digital Biomarkers are changing the face of Clinical trials. Digital Biomarkers will at a minimum,face the same regulatory challenges as traditional Biomarkers.There is a great potential to apply Digital Biomarkers to medical domains that are not very well understood such as pyschiatry and neurology. They can be used to explain ,influence and or predict health related outcomes.

  • Track 8-1Digital Biomarkers in drug development
  • Track 8-2Regulatory aspects for medical app development: Commercialization and Clinical Trial Use
  • Track 8-3Digital end points in clinical trials
  • Track 8-4Biosensors & wearables as Biomarker: Clinical development, Applications & Case studies

Exosomes are  released from the cell when multi vesicular bodies fuse with the plasma membrane . Exosomes have specialized functions and play a key role in processes such as coagulation, intercellular signalling, and waste management. They are being recognized as potential therapeutics as they have the ability to elicit potent cellular responses in vitro and in vivo. Compared with biomarkers identified in conventional specimens such as serum or urine, exosomal biomarkers provide the highest amount of sensitivity and specificity, which can be attributed to their excellent stability. The molecular constituents of exosomes, especially exosomal proteins and microRNAs (miRNAs), are promising as biomarkers in clinical diagnosis.


  • Track 9-1Exosomes and diagnosis of diseases like prion diseases, Epstein–Barr virus (EBV), kidney-related diseases etc.
  • Track 9-2Exosomal biomarkers for monitoring immunological rejection of tissue grafts.
  • Track 9-3Circulating Exosomes as new biomarkers for neurodegenerative disease or brain injury diagnosis.
  • Track 9-4Exosome-based approaches for diagnosis of cancers like: Colorectal Cancer and gastrointestinal cancer.
  • Track 9-5Exosomal microRNAs as biomarkers.
  • Track 9-6Exosomes and nanotheranostics.

A reliable Therapeutic biomarker would facilitate the individualization of current management algorithms, ensure that pathogenic mechanisms were disrupted or eliminated prior to treatment withdrawal, and reduce the frequency of relapse or unnecessary protracted therapy.Hence there are various researches in progress to discover new Biomarkers for various disease starting from autoimmune disorders to cardiovascular and Genetic disorders.


  • Track 10-1Emerging Biomarkers for personalized immunotherapies
  • Track 10-2Emerging therapeutic biomarkers in Cancers: Endometrial Cancer, Ovarian cancer, Melanoma, Non-small cell lung cancer, Endometrial Carcinoma, Lung Cancer etc.
  • Track 10-3Role of Emerging Biomarkers towards Unraveling the Complex Biology of various diseases
  • Track 10-4Cancer epigenetics as an emerging Biomarker
  • Track 11-1Drug development and usage
  • Track 11-2Cancer genomics
  • Track 11-3Personalized Medicine for treating Metabolomics Disorders, Genetic disorders, neurological disorders and immune disorders.
  • Track 11-4Personalized medicine using DNA biomarkers.
  • Track 11-5Bioinformatics in Personalized Medicine.
  • Track 11-6Bioinformatics in Personalized Medicine.
  • Track 11-7Bioinformatics in Personalized Medicine.